Literature DB >> 10716229

Intranuclear inclusions in subtypes of striatal neurons in Huntington's disease transgenic mice.

C M Kosinski1, J H Cha, A B Young, L Mangiarini, G Bates, J Schiefer, M Schwarz.   

Abstract

R6/2 transgenic mice express exon 1 of an abnormal human Huntington's disease (HD) gene and develop a neurological phenotype similar to HD. These mice develop ubiquitinated neuronal intranuclear inclusions (NII) which might play a central role in the pathophysiology of HD. We studied the distribution of NII in subpopulations of striatal neurons in 12-week-old R6/2 transgenic mice using fluorescent double label immunohistochemistry. We observed that most of the Calbindin-D28K positive projection neurons (89%) and the Parvalbumin positive interneurons (86%) showed ubiquitinated NII. In interneurons, however, which contain either choline acetyltransferase, neuronal nitric oxide synthase, or Calretinin, the frequency of NII was much lower (22%, 8%, 9%, respectively). Our data suggest that subpopulations of striatal neurons differ remarkably in their capability of forming ubiquitinated NII. Interneurons which are known to resist neurodegeneration in HD show less NII.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10716229     DOI: 10.1097/00001756-199912160-00031

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  11 in total

1.  Parvalbumin deficiency and GABAergic dysfunction in mice lacking PGC-1alpha.

Authors:  Elizabeth K Lucas; Sean J Markwardt; Swati Gupta; James H Meador-Woodruff; Jiandie D Lin; Linda Overstreet-Wadiche; Rita M Cowell
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

2.  Striatal GABAergic interneuron dysfunction in the Q175 mouse model of Huntington's disease.

Authors:  Sandra M Holley; Laurie Galvan; Talia Kamdjou; Carlos Cepeda; Michael S Levine
Journal:  Eur J Neurosci       Date:  2018-12-10       Impact factor: 3.386

3.  Motor function and dopamine release measurements in transgenic Huntington's disease model rats.

Authors:  Andrea N Ortiz; Gregory L Osterhaus; Kelli Lauderdale; Luke Mahoney; Stephen C Fowler; Stephan von Hörsten; Olaf Riess; Michael A Johnson
Journal:  Brain Res       Date:  2012-02-24       Impact factor: 3.252

Review 4.  The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.

Authors:  Jia Yi Li; Natalija Popovic; Patrik Brundin
Journal:  NeuroRx       Date:  2005-07

5.  Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length.

Authors:  Luis Pereira de Almeida; Christopher A Ross; Diana Zala; Patrick Aebischer; Nicole Déglon
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

6.  A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.

Authors:  Danielle A Simmons; Nadia P Belichenko; Tao Yang; Christina Condon; Marie Monbureau; Mehrdad Shamloo; Deqiang Jing; Stephen M Massa; Frank M Longo
Journal:  J Neurosci       Date:  2013-11-27       Impact factor: 6.167

7.  EGF amplifies the replacement of parvalbumin-expressing striatal interneurons after ischemia.

Authors:  Tetsuyuki Teramoto; Jianhua Qiu; Jean-Christophe Plumier; Michael A Moskowitz
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

8.  Enhanced GABAergic Inputs Contribute to Functional Alterations of Cholinergic Interneurons in the R6/2 Mouse Model of Huntington's Disease.

Authors:  Sandra M Holley; Prasad R Joshi; Anna Parievsky; Laurie Galvan; Jane Y Chen; Yvette E Fisher; My N Huynh; Carlos Cepeda; Michael S Levine
Journal:  eNeuro       Date:  2015 Jan-Feb

9.  Selective Sparing of Striatal Interneurons after Poly (ADP-Ribose) Polymerase 1 Inhibition in the R6/2 Mouse Model of Huntington's Disease.

Authors:  Emanuela Paldino; Antonella Cardinale; Vincenza D'Angelo; Ilaria Sauve; Carmela Giampà; Francesca R Fusco
Journal:  Front Neuroanat       Date:  2017-08-02       Impact factor: 3.856

10.  A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice.

Authors:  Danielle A Simmons; Nadia P Belichenko; Ellen C Ford; Sarah Semaan; Marie Monbureau; Sruti Aiyaswamy; Cameron M Holman; Christina Condon; Mehrdad Shamloo; Stephen M Massa; Frank M Longo
Journal:  Hum Mol Genet       Date:  2016-11-15       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.